

Principal Investigator/Program Director (Last, first, middle): Kinrys, Gustavo

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.  
Follow the sample format on preceding page for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Gustavo Kinrys, M.D.	Medical Director, Portuguese Mental Health Clinic; Director, Depression and Anxiety Disorders Research Program, Cambridge Health Alliance, Harvard Medical School

  

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Federal University of Rio de Janeiro, Brazil	M.D.	1996	Medicine
Mayo Graduate School of Medicine, Rochester, MN		1998-2001	Psychiatry
Massachusetts General Hospital, Boston, MA		2001-2002	Psychiatry
Massachusetts General Hospital, Boston, MA		2002-2003	Psychopharmacology Fellowship

### A. Positions and Honors.

#### Positions and Employment

- 2003- Medical Director, Portuguese Mental Health Clinic, Cambridge Health Alliance  
2003- Director, Depression and Anxiety Disorders Research Program, Cambridge Health Alliance  
2003- Instructor in Psychiatry, Harvard Medical School

#### Other Experience and Professional Memberships

- 2001- 2003 Investigator, Anxiety Disorders Program, Department of Psychiatry, MGH.  
1997-1998 Investigator, Anxiety and Depression Research Program, Institute of Psychiatry/UFRJ.

#### Honors

- 1993-1994 National Council for Scientific Research (CNPq) Award  
1994 Teacher Assistant/UFRJ Scholarship, Department of Pathology  
1994 County Health General Office, Academic Award  
1995-1996 Teacher Assistant/UFRJ Scholarship, Department of Psychiatry  
1999-2000 Howard P. Rome Scholarly Writing Award, Mayo Clinic  
2000 NIMH Outstanding Resident Award  
2000-2001 Howard P. Rome Scientific Writing Award, Mayo Clinic  
2002 Society of Biological Psychiatry Fellowship Award  
2002 APA/APIRE Minority Fellowship Program  
2002 Anxiety Disorders Association of America (ADAA) Travel Award  
2002 NIMH/NCDEU New Investigator's Program Award

### B. Peer-Reviewed Publications.

1. Kinrys G, Nardi AE et al: Valproic acid in the treatment of Panic disorder. Brazilian Journal of Psychiatry, 44(11): 589-592, 1995.

2. Kinrys G, Nardi AE et al: Valproic acid: Review of its pharmacological properties. *Brazilian Journal of Psychiatry*, 44(10): 533-538, 1995.
3. Mendlowicz M, Kinrys G, et al: Inefficacy of valproate in the treatment of Social phobia. *Brazilian Journal of Psychiatry*, 44(12): 643-645, 1995.
4. Marques C, Nardi AE, Kinrys G et al: Acute dystonic reaction with fluoxetine: case report. *Brazilian Journal of Psychiatry* 45(1): 51-54, 1996.
5. Marques C, Nardi AE, Kinrys G et al: SSRIs and weight gain. *Brazilian Journal of Psychiatry* 45(2): 111-114, 1996.
6. Nardi AE, Andrade Y, Kinrys G et al: Generalized anxiety disorder: theoretical and diagnostic principles. *Brazilian Journal of Psychiatry* 45(3): 173-178, 1996.
7. Nardi AE, Andrade Y, Kinrys G et al: Generalized anxiety disorder: clinical cases and treatment. *Brazilian Journal of Psychiatry* 45(4): 237-240, 1996.
8. Maurat A, Nardi AE, Kinrys G et al: Biological aspects of posttraumatic stress. *Brazilian Journal of Psychiatry* 45(5): 297-302, 1996.
9. Valença A, Andrade Y, Kinrys G et al: Panic disorder and respiration. *Brazilian Journal of Psychiatry* 45(8): 491-496, 1996.
10. Kinrys G, Bostwick JM, Steroid-responsive delirium associated with thyroiditis. *Psychosomatics*, December 2001 42(6):522-524.
11. Simon NM, Korbly NB, Worthington JW, Kinrys G, and Pollack MH. Citalopram for Social Anxiety Disorder: an Open-Label Pilot Study in Refractory and Non-Refractory Patients. *CNS Spectrums* 2002; 7(9): 655-662.
12. Kinrys G, Pollack MH, Simon N, Worthington JW, Nardi AE, Versiani M: Valproic acid for the treatment of Social Anxiety Disorder. *International Clinical Psychopharmacology* 2003;18(3):169-72.
13. Simon NM, Emanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, Farach FJ, and Pollack MH. Bupropion Sustained Release for Panic Disorder. *Psychopharmacology Bulletin*, 2003; 37(4):66-72.
14. Simon NM, Worthington JW, Reese H, Kinrys G, Pollack MH. An Open-Label Study of Levetiracetam for the Treatment of Social Anxiety Disorder. *Journal of Clinical Psychiatry*, 2004; 65(9):1219-22.
15. Kinrys G, Wygant L, Nery F, Pardo T, Melo M. Tiagabine for Treatment Refractory Social Anxiety Disorder. *Psychiatry Research*. In Press.
16. Worthington JW, Kinrys G, Wygant L, Pollack M. Aripiprazole as an Augmentor in Refractory Depression and Anxiety. *International Clinical Psychopharmacology* 2005 Jan; 20(1):9-11.
17. Kinrys G, Wygant LE. [Anxiety disorders in women: does gender matter to treatment?] *Rev Bras Psiquiatr*. 2005 Oct;27 Suppl 2:S43-50. Epub 2005 Nov 10.

18. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. *J Clin Psychiatry*. 2005 Oct;66(10):1326-30.
19. Kinrys G, Wygant LE. Anticonvulsants in anxiety disorders. *Curr Psychiatry Rep*. 2005 Aug;7(4):258-67.
20. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH. An open-label trial of risperidone augmentation for refractory anxiety disorders. *J Clin Psychiatry*. 2006 Mar;67(3):381-5.
21. Papakostas GI, Worthington JJ 3rd, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. *Depress Anxiety*. 2006;23(3):178-81.
22. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. *Biol Psychiatry*. 2006 Feb 1;59(3):211-5.
23. Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. *J Clin Psychiatry*. 2006 Feb;67(2):211-4.
24. Kinrys G. Levetiracetam: A critical review of the literature. *Expert Opinions Journal*. July 2007. In press.
25. Kinrys G and Rothstein E. Antipsychotics for Treatment Refractory Anxiety: Clinical Use and Applications. *Psychiatric Times*. July 2007. In press.
26. Kinrys G and Bianco R. Treatment Refractory Anxiety: Diagnosis and Treatment. *Current Psychiatry*. July 2007. In press.
27. Kinrys G, Vasconcelos DS, Nery F. Zonisamide for Treatment Refractory Anxiety. *International Journal of Clinical Practice*. June 2007.
28. Kinrys G, Worthington JW, Reese H, Simon NM, Doyle A, Melo M, Pollack MH. Levetiracetam for Treatment Refractory Anxiety Disorders. *J Clin Psychiatry*. 2007 Jun;68(6):1326-30.
29. Fiszman A, Marques C, Mendlowicz M, Kinrys G, Figueira I. Treatment Refractory Posttraumatic Stress Disorder. *Revista Brasileira de Psiquiatria*. July 2007. In press.
30. Pollack MH, Kinrys G, Krystal A et al. Evaluation of Eszopiclone and Escitalopram Oxalate Co-therapy in Patients with Insomnia and Comorbid Generalized Anxiety Disorder. *Archives of General Psychiatry*. In press.